Clinical Development of CRISPR-CAS3 Phage Cocktail for the Treatment of Recurrent Urinary Tract Infections…
FY2020 · complete year · data as of 2026-07-12
A single federal award, with both ends of the trail linked.
Award 75A50120C00169 is a contract from the Department of Health and Human Services, $73.9M obligated, FY2020 to FY2027, for Clinical Development of CRISPR-CAS3 Phage Cocktail for the Treatment of Recurrent Urinary Tract…. The work is performed in North Carolina. It is classified as NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)) and PSC AN13 (Health R&D Services; Health Care Services; Experimental Development). Source
Description
Clinical Development of CRISPR-CAS3 Phage Cocktail for the Treatment of Recurrent Urinary Tract Infections Caused by Escherichia Coli Including Antimicrobial and Multi-Drug Resistant Strains